Ophthalmic preparation GB10 injection receives clinical trial approval notice
December 9, 2025
Source: drugdu
34
Securities Daily Online News On the evening of December 8th, Sinovac Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Shenzhen Sinovac Pharmaceutical Co., Ltd., recently received a "Notice of Drug Clinical Trial Approval" from the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Sinovac to carry out clinical trials for the "GB10 Injection".
https://finance.eastmoney.com/a/202512083585556010.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- How to Use B2B Platforms to Expand Global Sales Channels December 10, 2025
- WHO releases guidelines for the use of new weight-loss drugs December 9, 2025
- Grand Pharmaceutical’s Class 1 innovative traditional Chinese medicine drug GPN01360 has reached its clinical endpoint in the Phase II clinical trial in China December 9, 2025
- Incyte Pharma Drug Shows Positive Effect in Treatment of a Certain Type of Blood Cancer December 9, 2025
- Huadong Medicine enters commercialization partnership with Sinorda Pharma December 9, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
